Authors
Latest:
Mascarenhas on the SENTRY Trial Design and GoalsJohn Mascarenhas, MD, discusses the methods, design, and inclusion criteria of the phase 3 SENTRY trial for patients with JAK inhibitor treatment-naive myelofibrosis.
Latest:
Dr. John McCarty on Advice for Patients With Lymphoma Seeking Stem Cell Mobilization​John McCarty, MD, medical director, Bone Marrow Transplant Program, Virginia Commonwealth University Health, discusses advice physicians can give to patients with lymphoma seeking stem cell mobilization.
Latest:
Pooled Analysis of Ibrutinib Shows Long-Term Efficacy in CLLJohn N. Allan, MD, discusses a pooled analysis of 4 clinical trials with 4-year follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia and TP53 aberration deletion 17p or a TP53 mutation.
Latest:
Exploring the Treatment Landscape for Myeloproliferative NeoplasmsJohn O. Mascarenhas, MD, discusses the current treatment options for patients with myelofibrosis.
Latest:
Expanding the Reach of Immunotherapies for Kidney CancerDavid F. McDermott, MD, discusses methods of expanding on progress seen in the field of immunotherapy, both in the case of kidney cancer and other tumor types at the PER® European Congress on Immunotherapies in Cancer held in Barcelona.
Latest:
Addressing Treatment Gaps in Follicular LymphomaDr John P. Leonard highlights ongoing clinical trials and therapies of interest in the follicular lymphoma pipeline and explains how progress in the field will help address ongoing treatment challenges.
Latest:
A Subgroup Analysis of the FALCON Trial for HR+ Breast CancerJohn Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant versus anastrozole in patients with HR-positive advanced breast cancer.
Latest:
Dr. John Zalcberg on Regorafenib in Refractory Advanced Oesophago-Gastric Cancer PatientsJohn Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about the poor prognosis of refractory advanced oesophago-gastric cancer (AOGC) patients and how regorafenib could benefit those patients.
Latest:
Study Shows AKT1 E17K a Targetable Mutation Through AKT Inhibition Across Various Cancer TypesAmultihistology basket study proved the targetability of the <em>AKT1 E17K</em> mutation in human cancers by treating patients with various types of cancer harboring an <em>AKT1 E17K </em>mutation with AZD5363, an oral pan-AKT inhibitor, according to findings published in the <em>Journal of Clinical Oncology</em>.
Latest:
Overview of the INTRIGUE Study of Ripretinib vs Sunitinib in GISTJonathan C. Trent, MD, PhD, discusses the methods, design, and results from the INTRIGUE study in advanced gastrointestinal stromal tumor.
Latest:
A 15,000-Patient Survey Looking at Breast Cancer Risk PerceptionJonathan D. Herman, MD, obstetrician and gynecologist at Hofstra North Shore - LIJ Medical School, discusses the findings from a survey looking at breast cancer risk perception.
Latest:
Study Design and Inclusion Criteria of the EV-103 Study in Advanced Urothelial CarcinomaJonathan E. Rosenberg, MD, explains the study design and patient inclusion criteria of the phase 2 EV-103 study investigating combination enfortumab vedotin plus pembrolizumab for the treatment of patients with metastatic or locally advanced urothelial carcinoma.
Latest:
SWOG S1826: Frontline N-AVD vs BV-AVD in Advanced Hodgkin’s LymphomaSwitching their focus to the SWOG S1826 clinical trial in Hodgkin’s Lymphoma, Rohit Gosain, MD, Rahul Gosain, MD, and Jonathan Friedberg, MD, MMSc, consider the role of frontline R-AVD versus BV-AVD.
Latest:
Rucaparib May Improve PFS in Patients With Ovarian CancerJonathan Ledermann, MD, professor of oncology, UCL Cancer Institute, University College London, discusses the results of a subanalysis from the phase III ARIEL trial of rucaparib maintenance treatment for patients with recurrent ovarian carcinoma.
Latest:
Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETsThe trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Latest:
The Incidence and Survival Trends of Thymic MalignanciesJonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses a population-based study of incidence and survival trends of 1261 thymic malignancies from the California Cancer Registry.
Latest:
Dr. Jonathan Schoenfeld of Synergy of Chemotherapy and Immunotherapy in Head and Neck CancerJonathan Schoenfeld, MD, MPH, discusses the immunologic effects of chemotherapy plus radiation, as well as radiation alone.
Latest:
Using Capecitabine/Temozolomide or 177Lu-Dotatate to Treat NETs Requires Real-World GuideA real-world guide to best practices in treating neuroendocrine tumors can improve patient outcomes.
Latest:
Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue SarcomasDr. Jonathan Trent discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Latest:
Riess on the FAVOUR Trial Furmonertinib in EGFR Exon20Ins Mut+ NSCLCJonathan W. Riess, MD, medical director of thoracic oncology, University of California, Davis Comprehensive Cancer Center, discusses the phase 1b FAVOUR trial of furmonertinib in patients with advanced non–small cell lung cancer harboring EGFR Exon20 insertion mutations.
Latest:
Overcoming Challenges in Treating MCLJonathon B. Cohen, MD, discusses the biggest challenge in treating mantle cell lymphoma and how these challenges can be overcome.
Latest:
Discussing Reimbursement Barriers for FLT3 Mutation Analysis<em>FLT3</em> mutation analysis in laboratories has brought on reimbursement barriers in clinical oncology. Jordan Clark, chief commercial officer, Diaceutics, a diagnostic development and commercialization company, spoke to <em>Targeted Oncology</em> about the cause of reimbursement issues and how the problem affects all parties involved.
Latest:
Rationale for Ibrutinib/CAR T-Cell Therapy Combination in CLLJordan Gauthier, MD, MSc, discusses the rationale for combining ibrutinib with CD19-targeting chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.
